Oxurion NV (OXUR.BR)
EUR 0.27
(0.0%)
EUR 0.27
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -18.96 Million EUR | 40.13% |
| 2022 | -31.68 Million EUR | -8.67% |
| 2021 | -29.15 Million EUR | -4.09% |
| 2020 | -28.01 Million EUR | 45.95% |
| 2019 | -51.82 Million EUR | -34.71% |
| 2018 | -38.47 Million EUR | -268.83% |
| 2017 | 22.78 Million EUR | 137.78% |
| 2016 | -60.31 Million EUR | -59.21% |
| 2015 | -37.88 Million EUR | 25.88% |
| 2014 | -51.11 Million EUR | -293.61% |
| 2013 | 26.4 Million EUR | -13.2% |
| 2012 | 30.41 Million EUR | 240.57% |
| 2011 | -21.63 Million EUR | -55.19% |
| 2010 | -13.94 Million EUR | 0.91% |
| 2009 | -14.07 Million EUR | -216.33% |
| 2008 | 12.09 Million EUR | 175.75% |
| 2007 | -15.96 Million EUR | -57.56% |
| 2006 | -10.13 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.02 Million EUR | 0.0% |
| 2023 Q2 | -10.62 Million EUR | 0.0% |
| 2023 Q4 | -8.34 Million EUR | 0.0% |
| 2023 FY | -18.96 Million EUR | 40.13% |
| 2022 FY | -31.68 Million EUR | -8.67% |
| 2022 Q2 | -14.48 Million EUR | 0.0% |
| 2022 Q4 | -17.2 Million EUR | 0.0% |
| 2021 Q2 | -15.85 Million EUR | 0.0% |
| 2021 Q4 | -13.3 Million EUR | 0.0% |
| 2021 FY | -29.15 Million EUR | -4.09% |
| 2020 FY | -28.01 Million EUR | 45.95% |
| 2020 Q4 | -14.87 Million EUR | 0.0% |
| 2020 Q2 | -13.13 Million EUR | 0.0% |
| 2019 Q2 | -33.31 Million EUR | 0.0% |
| 2019 Q4 | -18.51 Million EUR | 0.0% |
| 2019 FY | -51.82 Million EUR | -34.71% |
| 2018 Q2 | -15.02 Million EUR | 0.0% |
| 2018 Q4 | -23.44 Million EUR | 0.0% |
| 2018 FY | -38.47 Million EUR | -268.83% |
| 2017 Q4 | 38 Million EUR | 0.0% |
| 2017 FY | 22.78 Million EUR | 137.78% |
| 2017 Q2 | -15.21 Million EUR | 0.0% |
| 2016 Q4 | -45.29 Million EUR | 0.0% |
| 2016 Q2 | -15.01 Million EUR | 0.0% |
| 2016 FY | -60.31 Million EUR | -59.21% |
| 2015 FY | -37.88 Million EUR | 25.88% |
| 2015 Q4 | -18.7 Million EUR | 0.0% |
| 2015 Q2 | -19.17 Million EUR | 0.0% |
| 2014 Q4 | -27.26 Million EUR | 0.0% |
| 2014 Q2 | -23.84 Million EUR | 0.0% |
| 2014 FY | -51.11 Million EUR | -293.61% |
| 2013 Q2 | 54.6 Million EUR | 0.0% |
| 2013 Q4 | -28.2 Million EUR | 0.0% |
| 2013 FY | 26.4 Million EUR | -13.2% |
| 2012 Q1 | 7.6 Million EUR | 0.0% |
| 2012 FY | 30.41 Million EUR | 240.57% |
| 2012 Q4 | 6.6 Million EUR | -13.2% |
| 2012 Q2 | 7.6 Million EUR | 0.0% |
| 2012 Q3 | 7.6 Million EUR | 0.0% |
| 2011 Q4 | 7.6 Million EUR | 240.57% |
| 2011 Q1 | -5.4 Million EUR | 0.0% |
| 2011 Q2 | -5.4 Million EUR | 0.0% |
| 2011 FY | -21.63 Million EUR | -55.19% |
| 2011 Q3 | -5.4 Million EUR | 0.0% |
| 2010 FY | -13.94 Million EUR | 0.91% |
| 2010 Q2 | -3.48 Million EUR | 0.0% |
| 2010 Q1 | -3.48 Million EUR | 0.0% |
| 2010 Q3 | -3.48 Million EUR | 0.0% |
| 2010 Q4 | -5.4 Million EUR | -55.19% |
| 2009 Q1 | -3.51 Million EUR | 0.0% |
| 2009 FY | -14.07 Million EUR | -216.33% |
| 2009 Q3 | -3.51 Million EUR | 0.0% |
| 2009 Q2 | -3.51 Million EUR | 0.0% |
| 2009 Q4 | -3.48 Million EUR | 0.91% |
| 2008 Q4 | -3.51 Million EUR | -216.33% |
| 2008 FY | 12.09 Million EUR | 175.75% |
| 2008 Q1 | 3.02 Million EUR | 0.0% |
| 2008 Q2 | 3.02 Million EUR | 0.0% |
| 2008 Q3 | 3.02 Million EUR | 0.0% |
| 2007 Q3 | -3.99 Million EUR | 0.0% |
| 2007 Q4 | 3.02 Million EUR | 175.75% |
| 2007 FY | -15.96 Million EUR | -57.56% |
| 2007 Q2 | -3.99 Million EUR | 0.0% |
| 2007 Q1 | -3.99 Million EUR | 0.0% |
| 2006 Q4 | -3.99 Million EUR | -57.56% |
| 2006 FY | -10.13 Million EUR | 0.0% |
| 2006 Q3 | -2.53 Million EUR | 0.0% |
| 2006 Q2 | -2.53 Million EUR | 0.0% |
| 2006 Q1 | -2.53 Million EUR | 0.0% |
| 2005 Q4 | -2.53 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -439.198% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 87.161% |
| Adocia SA | -21.16 Million EUR | 10.363% |
| Aelis Farma SA | -5.07 Million EUR | -273.553% |
| Biophytis S.A. | -17.02 Million EUR | -11.412% |
| Advicenne S.A. | -7.03 Million EUR | -169.791% |
| genOway Société anonyme | 1.56 Million EUR | 1310.086% |
| IntegraGen SA | -171.39 Thousand EUR | -10967.159% |
| Medesis Pharma S.A. | -3.95 Million EUR | -379.077% |
| Neovacs S.A. | -8.74 Million EUR | -116.951% |
| NFL Biosciences SA | -3.74 Million EUR | -406.451% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 24060.136% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -498.212% |
| Sensorion SA | -22.06 Million EUR | 14.025% |
| Theranexus Société Anonyme | -6.82 Million EUR | -177.814% |
| TME Pharma N.V. | -6.73 Million EUR | -181.606% |
| Valbiotis SA | -7.36 Million EUR | -157.451% |
| TheraVet SA | -1.57 Million EUR | -1107.673% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 6.759% |
| argenx SE | -272.91 Million EUR | 93.049% |
| BioSenic S.A. | -28.77 Million EUR | 34.085% |
| Celyad Oncology SA | -8.44 Million EUR | -124.538% |
| DBV Technologies S.A. | -67.26 Million EUR | 71.801% |
| Galapagos NV | 211.69 Million EUR | 108.96% |
| Genfit S.A. | -28.89 Million EUR | 34.35% |
| GeNeuro SA | -14.75 Million EUR | -28.542% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -23.336% |
| Innate Pharma S.A. | -7.57 Million EUR | -150.581% |
| Inventiva S.A. | -110.42 Million EUR | 82.822% |
| MaaT Pharma SA | -19.71 Million EUR | 3.794% |
| MedinCell S.A. | -25.03 Million EUR | 24.239% |
| Nanobiotix S.A. | -39.7 Million EUR | 52.219% |
| Onward Medical N.V. | -36.18 Million EUR | 47.572% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -465.742% |
| OSE Immunotherapeutics SA | -23 Million EUR | 17.537% |
| Pharming Group N.V. | -9.75 Million EUR | -94.422% |
| Poxel S.A. | -35.09 Million EUR | 45.942% |
| GenSight Biologics S.A. | -26.22 Million EUR | 27.654% |
| Transgene SA | -22.32 Million EUR | 15.044% |
| Financière de Tubize SA | 88.15 Million EUR | 121.519% |
| UCB SA | 343 Million EUR | 105.53% |
| Valneva SE | -101.42 Million EUR | 81.298% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 33.071% |